Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic Leukemia

NCT00154349 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Philadelphia Chromosome Positive Acute Lymphocytic Leukemia

Interventions

DRUG: Imatinib Mesylate

Sponsor

Novartis Pharmaceuticals